Background: The intranasal (IN) route for rapid drug administration in patients with brain disorders, including status epilepticus, has been investigated. Status epilepticus is an emergency, and the IN route offers a valuable alternative to other routes, especially when these fail.
Animals: Client-owned dogs (n = 44) with idiopathic epilepsy, structural epilepsy, or epilepsy of unknown origin manifesting as status epilepticus.
Methods: Randomized parallel group clinical trial. Patients were randomly allocated to the IN-MDZ (n = 21) or IV-MDZ (n = 23) group. Number of successfully treated cases (defined as seizure cessation within 5 minutes and lasting for ≥10 minutes), seizure cessation time, and adverse effects were recorded. Comparisons were performed using the Fisher's exact and Wilcoxon rank sum tests with statistical significance set at α < .05. well as its potential to circumvent the blood-brain barrier (BBB), the intranasal (IN) route might offer an advantageous and novel way to directly and quickly deliver drugs to the brain to treat various disorders. [1] [2] [3] [4] [5] [6] [7] Intranasal drug delivery has been widely investigated for anesthetic purposes, and experimental studies have reported that it can be effectively used for analgesia (IN-fentanyl), 8 sedation (IN-xylazine, 9 IN-medetomidine/ketamine, 10 IN-ketamine, 11, 12 ) and sedation and opioid reversal (IN-atipamezole/IN-naltrexone). 13 Benzodiazepines (eg, midazolam [MDZ]), are used commonly as a first-line management option for status epilepticus in humans and dogs. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Midazolam, a water-soluble benzodiazepine, is considered an effective and safe anti-seizure drug when administered by the IN, IV, or IM routes. 15, 18, [20] [21] [22] [23] [24] Intranasal MDZ can be useful or even life-saving, especially when IV access is not available. 15, 25 Intranasal MDZ has been reported to be an effective and safe choice as a sedative drug in children undergoing diagnostic and minor surgical procedures. [26] [27] [28] [29] It also has been shown to suppress epileptic spike activity on electroencephalograms of epileptic children. 30 Based on clinical trials, which evaluated the efficacy of IN-MDZ, it was concluded that IN-MDZ was effective and safe for terminating status epilepticus in humans and that it can be used not only by clinicians in the hospital environment but also by families at home. 22, 31 It was recently demonstrated that IN-MDZ was effective and safe as well as superior to rectally administered diazepam for the management of status epilepticus in dogs with idiopathic epilepsy, structural epilepsy, or epilepsy of unknown origin. 15 In the present study, we compared MDZ given at the same dose but by different routes (IN or IV) for the treatment of status epilepticus in dogs. Our aim was to provide further evidence of the potential efficacy and safety of IN-MDZ in dogs with status epilepticus and compare it to the gold standard of IV administration to evaluate if a significant difference existed between the 2 routes in the time needed to terminate the epileptic seizures.
Results

| MATERIALS AND METHODS
The methodology we used was similar to that of a previous trial of IN-MDZ, which has been described previously. 15 The current study was an open-label randomized parallel group clinical trial including clientowned dogs and approved by the enrolling universities' ethical committees. Owner information and consent forms for the study were completed. Dogs with status epilepticus manifesting generalized or focal epileptic seizures with any type of motor activity (ie, tonic-clonic or myoclonic) caused by idiopathic epilepsy, structural epilepsy, or epilepsy of unknown origin were included. Dogs with reactive seizures associated with metabolic or toxic causes or dogs that had received any drugs before 5 minutes of continuous epileptic seizure activity had passed were excluded. Classification of epilepsy types, clinical signs, and diagnostic approach were based on the International Veterinary Epilepsy Task Force consensus reports. 32, 33 In particular, for the diagnosis of idiopathic epilepsy, classification into 3 tiers of confidence was performed based on history, signalment, and unremarkable interictal neurological examination, blood tests, brain magnetic resonance imaging, and cerebrospinal fluid analysis. 33 Status epilepticus was defined as a continuous epileptic seizure lasting more >5 minutes, or ≥2 discrete epileptic seizures between which incomplete recovery of consciousness occurred. 32 Dogs that manifested status epilepticus were randomly assigned to IN-MDZ or IV-MDZ groups, using randomized sealed envelopes. Midazolam was administered at the same dosage for both routes (ie, 0.2 mg/kg) after at least 5 minutes of continuous seizure activity. In the dogs allocated to the IV-MDZ group, an IV catheter, if not already present, was placed immediately. In the IN-MDZ group, an IV catheter was placed after MDZ administration to provide IV access. All dogs were treated and remained in a hospital environment for constant observation and monitoring for at least 1 hour after benzodiazepine administration.
3 | OUTCOME ASSESSMENT
| Primary outcomes
The outcome measurements included:
1. "Seizure cessation" time, defined as the time between drug administration and seizure cessation. was >10 minutes. 15 For the unsuccessful cases, the protocol was no longer applicable and additional anti-seizure drugs could be given as directed by the clinician in charge.
| Secondary outcomes
1. Complications and adverse effects. Heart rate and rhythm, respiratory rate and pattern, blood pressure (by use of Doppler) and oxygen saturation (by use of pulse oximetry) were measured 5 (T5) and 3. Further information, such as history of antiepileptic drugs and duration of dogs' seizure activity before inclusion in the trial, was recorded.
| Statistical analysis
As in a previous trial, 15 the primary outcomes evaluated were the number of successful cases in each group and seizure cessation times.
Statistical analysis was conducted using the statistical software R (ver- 
| RESULTS
| Signalment and baseline characteristics of study subjects and disease characterization
Details of signalment, clinical findings, and disease characteristics of the included cases are provided in Table 1 . Table 2 .
| Primary and secondary outcomes
| DISCUSSION
Our humans as well as in animals. 15, 22, 25, 31, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Studies in epileptic humans that compared IN to IV administration of benzodiazepines showed that both routes were effective for seizure cessation. 22, 31, 50 Specifically, IN-MDZ was as safe and effective as IV diazepam but, if the time to place an IV catheter was not taken into account, seizures were controlled more quickly with IV diazepam. In our study, we found that IN-MDZ was quicker than IV-MDZ, and the difference was significant when the time to place an IV catheter was taken into account. Lastly, a metaanalysis in human patients concluded that although there was minimal difference in the time interval from drug administration to clinical seizure cessation, which was shorter for diazepam by any route than for non-IV MDZ by any route, this difference was not clinically relevant. 51 Increasing interest in IN drug administration as a therapeutic option for brain and systemic diseases derives from the particular anatomical, physiological, and histological characteristics of the nasal cavity. Intranasal administration provides an opportunity for rapid systemic drug absorption and rapid onset of action as well as different and advantageous pathways through which the drug can reach the brain. 3, 6, [52] [53] [54] [55] [56] [57] The canine nasal cavity is divided by the nasal septum into 2 symmetric airways, each including the nasal vestibule, respiratory and olfactory regions. 58 The nasal vestibule has limited vascularization and permeability, which leads to poor absorption of substances such as drugs. 7, 58, 59 In contrast, the respiratory and olfactory regions have high vascularization and good permeability and, therefore, are the main sites of drug absorption. 7, 58 Although lipid-soluble small molecules can be absorbed more easily from the nasal cavity, many drugs targeting the brain are water-soluble small molecules or large molecules (>400 Da) that cannot freely pass through various mucosal barriers of the body including the nasal mucosa.
Midazolam is water-soluble (marketed solution pH = 3.5) but, after IN administration, becomes lipid-soluble (nasal cavity pH = 5.5-6.5 1, 60 ), and as a result it can cross the nasal mucosa and pass into the brain with a rapid onset of action. 25, 61, 62 After absorption, some amount of the drug will undergo clearance and drainage by the systemic circulation and nasal lymphatic vessels, and might not reach the brain. 52 The remaining amount passes into the circulation and reaches the BBB without being subject to the first-pass hepatic metabolism, which can enhance the drug's bioavailability. 22, 25, [62] [63] [64] [65] [66] [67] The BBB is an essential factor limiting the development of new drugs targeting the brain because it can restrict the influx of drugs into the brain. All large molecules (ie, >400 Da) and >98% of small molecules cannot penetrate the BBB 6, 54 and therefore cannot achieve adequate therapeutic concentrations in the brain after IV or PO administration. 68 Only a few lipid-soluble small molecules (<400 Da; e.g., benzodiazepines, phenobarbital) can penetrate the BBB by lipid-mediated free diffusion, treating specific disorders such as epilepsy. 69 Recent studies, however, showed that some proteins, 56, 57, 70 peptides, 71, 72 and oligonucleotides 73, 74 actually could reach the brain after IN administration, which supports the fact that these molecules potentially avoided the BBB. Bypassing the BBB, drugs that might not be able to enter the brain could benefit from IN administration and might require lower doses to be effective with fewer adverse effects. 75, 76 This could be a reason why in our study administration 0.2 mg/kg of MDZ IN resulted in an overall higher number of successfully treated cases compared to IV administration, although there was no statistically significant difference. In addition, bypassing the BBB might be beneficial for dogs with drug-resistant idiopathic epilepsy, because the BBB plays an important role in developing antiepileptic drug resistance (ie, because of overexpression of drug transporters such as P-glycoprotein and multidrug-resistance-associated protein). [77] [78] [79] Some molecules can avoid the BBB, enter the brain, and then be distributed to other brain areas from the point of entry, via the olfactory (within olfactory epithelium) and trigeminal (within respiratory epithelium) nerves. 52, 56, 57, 80 Various mechanisms of transport via these nerve pathways have been described. 56, 57, 81 Final distribution of the drug after brain entry points at the level of the olfactory bulb (via the olfactory nerve and nasal epithelium) and the brainstem (via the trigeminal nerve) to other areas of the brain is likely established by intracellular and extracellular transport mechanisms. [82] [83] [84] [85] Apart from the properties and advantages that the IN route offers to the administration of drugs that target the brain, another important aspect is the formulation and delivery method of the drug (ie, the nasal device). These factors can influence uptake of the drug by the brain. In our trial, similar to a previous study, 15 we used the MAD used in humans, to deliver the medication into the nasal cavity. This MAD is a type of a spray device that can be used like a syringe and delivers the drug as a very fine mist of 30-100 μm particles, enhancing the drug's absorption and bioavailability. 86, 87 88 Similarly to a previous trial, 15 all cases of meningoencephalitis of unknown origin and the 1 dog with focal epileptic seizures were unsuccessfully treated, although the small number of dogs in these categories precludes definite conclusions. Lastly, timedependent drug-resistant status epilepticus has been reported. 34 The anticonvulsant potency of benzodiazepines can decrease by 20-fold within 30 minutes of continuous seizure activity. 89 In our study, the dogs' median duration of epileptic seizure activity before the inclusion in the trial was 8 and 8.5 minutes in the IN-MDZ and IV-MDZ groups, respectively. This fact might have adversely affected the efficacy of MDZ in both groups compared to a situation in which MDZ had been administered earlier (ie, within 5 minutes), although a larger number of dogs would be necessary to draw firm conclusions. However, the waiting period of at least 5 minutes before administering MDZ was crucial in our study because, otherwise, it could be argued that the epileptic seizures ceased because they might have been self-limiting (ie, inclusion of non-status epilepticus cases) and not a consequence of the MDZ administration.
| CONCLUSION
Based on our study, both IN and IV MDZ are effective, quick, and safe first-line medications for controlling status epilepticus in dogs. Considering that establishing IV access in a dog with status epilepticus might be problematic or delay further treatment, IN-MDZ could be used as a firstline option, before IV access, for the treatment of status epilepticus in dogs either at the clinic or by owners at home. Despite some considerations with regard to a drug's absorption and delivery to the brain, the IN route offers several potential advantages. These include rapid use and onset of action, non-invasive and easy administration, a safe and effective method directly targeting the brain, and the ability to overcome the BBB. Further preclinical and clinical studies (including a larger number of subjects and different devices and drug dosages) focusing on this promising route should be performed to establish this therapeutic route for various brain disorders in dogs.
